In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis ...
Patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer who are not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback